Paysign’s (PAYS) Outperform Rating Reiterated at Barrington Research

Barrington Research reiterated their outperform rating on shares of Paysign (NASDAQ:PAYS) in a report issued on Wednesday,Benzinga reports. The firm currently has a $7.00 price objective on the stock.

Separately, Lake Street Capital assumed coverage on shares of Paysign in a research report on Friday, December 20th. They set a “buy” rating and a $6.00 price target on the stock.

Paysign Stock Performance

Paysign stock opened at $2.13 on Wednesday. Paysign has a fifty-two week low of $2.10 and a fifty-two week high of $5.59. The company has a market cap of $114.06 million, a PE ratio of 14.20 and a beta of 0.93. The business’s 50-day simple moving average is $2.62 and its two-hundred day simple moving average is $3.22.

Paysign (NASDAQ:PAYS) last posted its quarterly earnings results on Tuesday, March 25th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.02. The company had revenue of $15.61 million during the quarter, compared to analyst estimates of $15.42 million. Paysign had a net margin of 14.28% and a return on equity of 30.64%. As a group, analysts predict that Paysign will post 0.21 EPS for the current fiscal year.

Insider Transactions at Paysign

In other news, CEO Mark Newcomer sold 100,000 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $2.73, for a total value of $273,000.00. Following the completion of the sale, the chief executive officer now directly owns 8,936,886 shares in the company, valued at $24,397,698.78. This represents a 1.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Topline Capital Management, Ll sold 120,000 shares of the business’s stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $3.24, for a total transaction of $388,800.00. Following the transaction, the insider now owns 5,336,146 shares in the company, valued at $17,289,113.04. The trade was a 2.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 695,900 shares of company stock valued at $2,106,810 over the last 90 days. Corporate insiders own 23.40% of the company’s stock.

Hedge Funds Weigh In On Paysign

Large investors have recently modified their holdings of the business. Barclays PLC raised its stake in shares of Paysign by 327.4% in the 3rd quarter. Barclays PLC now owns 47,090 shares of the company’s stock valued at $173,000 after acquiring an additional 36,071 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Paysign by 164.1% in the third quarter. JPMorgan Chase & Co. now owns 63,247 shares of the company’s stock valued at $232,000 after buying an additional 39,299 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Paysign by 257.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 44,793 shares of the company’s stock valued at $164,000 after buying an additional 32,245 shares during the period. Sanctuary Advisors LLC grew its position in Paysign by 4.3% in the 3rd quarter. Sanctuary Advisors LLC now owns 121,089 shares of the company’s stock valued at $419,000 after acquiring an additional 5,000 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Paysign by 33.5% during the fourth quarter. SG Americas Securities LLC now owns 15,508 shares of the company’s stock worth $47,000 after purchasing an additional 3,895 shares in the last quarter. Institutional investors and hedge funds own 25.89% of the company’s stock.

Paysign Company Profile

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.